Abstract / Summary
To evaluate the efficacy and survival outcomes of TC chemotherapy combined with bevacizumab and tislelizumab in patients with recurrent cervical cancer. A total of 50 patients with recurrent cervical cancer treated between May 2019 and May 2023 were retrospectively analyzed. Patients were divided into two groups: the control group (TC chemotherapy + bevacizumab) and the study group (TC chemotherapy + bevacizumab + tislelizumab), with 25 patients in each group. Clinical efficacy, immune function indicators (CD3+, CD4+, CD8+), adverse reactions, recurrence rates, and survival outcomes were compared. Follow-up was conducted until May 2024. The study group demonstrated significantly improved clinical efficacy compared to the control group ( P < 0.05), with higher complete response rates and tumor-free survival. After treatment, the study group showed higher peripheral blood CD3 + and CD4 + levels and lower peripheral CD8 + levels than the control group ( P < 0.05), indicating a change in peripheral T-cell subset distribution. The incidence of severe adverse reactions, including myelosuppression and gastrointestinal toxicity, was lower in the study group during early treatment. Median overall survival (15.8 vs. 13.2 months; log-rank χ² = 4.92, P = 0.027) and progression-free survival (13.5 vs. 11.0 months; log-rank χ² = 5.14, P = 0.023) were significantly longer in the study group. The 1-year overall survival rates were 76.0% and 60.0%, and the 2-year overall survival rates were 32.0% and 16.0% in the study and control groups, respectively. The addition of tislelizumab to TC chemotherapy and bevacizumab significantly improves treatment efficacy, immune function, and survival outcomes in patients with recurrent cervical cancer, while maintaining an acceptable safety profile. This combined therapeutic approach shows promise as an effective strategy for managing recurrent cervical cancer.